- Home
- PBR vs SNY Comparison
PBR vs SNY Comparison
Compare PBR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBR | SNY |
|---|---|---|
| Founded | 1953 | 1994 |
| Country | Brazil | France |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.8B | 104.5B |
| IPO Year | 2015 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PBR | SNY |
|---|---|---|
| Price | $20.77 | $42.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $17.56 | ★ $58.00 |
| AVG Volume (30 Days) | ★ 21.4M | 2.0M |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | 3.31% | ★ 3.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.00 | $3.49 |
| Revenue Next Year | N/A | $6.10 |
| P/E Ratio | $13.55 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.43 | $40.89 |
| 52 Week High | $22.24 | $52.68 |
Technical Indicators
Market Signals| Indicator | PBR | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 38.53 |
| Support Level | $19.63 | $42.30 |
| Resistance Level | $21.92 | $45.22 |
| Average True Range (ATR) | 0.51 | 0.50 |
| MACD | -0.09 | -0.15 |
| Stochastic Oscillator | 9.63 | 0.70 |
Price Performance
Historical ComparisonAbout PBR Petroleo Brasileiro S.A.- Petrobras
Petrobras is a Brazil-based integrated energy company controlled by the Brazilian government. The company focuses on the exploration and production of oil and gas in Brazilian offshore fields. Production in 2025 was 3.0 million barrels of oil equivalent per day (80% oil), and reserves stood at 12.1 billion boe (84% oil). At the end of 2025, Petrobras operated 10 refineries in Brazil with a capacity of 1.8 million barrels per day and distributed refined products and natural gas throughout the country.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.